Inventor

TAGMOSE LENA

DK13 patents

⚠️ This page may combine multiple inventors who share the name “TAGMOSE LENA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

H LUNDBECK AS

11 patents

US11111290B2Sep 7, 2021

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

H LUNDBECK AS1 citations62

US12129289B2Oct 29, 2024

Antibodies specific for hyperphosphorylated tau and methods of use thereof

H LUNDBECK AS0 citations61

US10004738B2Jun 26, 2018

Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines

H LUNDBECK AS1 citations52

US10603310B2Mar 31, 2020

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

H LUNDBECK AS0 citations51

US10058540B2Aug 28, 2018

2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

H LUNDBECK AS1 citations51

US10059669B2Aug 28, 2018

2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease

H LUNDBECK AS1 citations51

US10011596B2Jul 3, 2018

2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

H LUNDBECK AS1 citations51

LUNDBECK & CO AS H

2 patents

US9353084B2May 31, 2016

2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease

LUNDBECK & CO AS H9 citations84

US9346797B1May 24, 2016

2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

LUNDBECK & CO AS H7 citations83

TAGMOSE LENA

H LUNDBECK AS

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Antibodies specific for hyperphosphorylated tau and methods of use

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

Antibodies specific for hyperphosphorylated tau and methods of use thereof

Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahydropyridines

2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer&#39;s disease

2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

LUNDBECK & CO AS H

2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer&#39;s disease

2-amino 6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors

2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treating alzheimer's disease

2-amino 3,5,5-trifluoro-3,4,5,6-tetrahydropyridines as BACE1 inhibitors for treatment of Alzheimer's disease